Sequoia China, a private equity firm, led a $37m Series A round in Full-Life Technologies, a fully integrated global radiotherapeutics company, with participation from Yunion Healthcare Ventures, Junson Capital, CD Capital and Kunlun Capital. "The funding from world-class venture investors like Sequoia China is a strong vote of confidence in our strategy, team and progress to date. The funds will enable us to advance our lead radiopharmaceutical compounds into first-in-human studies next year and accelerate the development of our global radioisotope production and logistics capabilities," Lanny Sun, Full-Life Co-founder, Chairman & Chief Executive Officer.